SEPN

Septerna Inc

38.91

Aug 28 • 3:59 PM ET -1.56 (-3.85%)

38.91

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: KYMR BMRN CRNX RYTM INCY KRYS VKTX AXSM MDGL NBIX

| Held by: VTI IWM VXF IBB XPH IWO SCHA VTWO IHE IWN

Index	RUT
Market Cap	1.82B
Enterprise Value	1.47B
Income	-24.24M
Sales	98.88M
Book/sh	8.47
Cash/sh	7.98
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	130
IPO	Oct 25, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	18.37
P/B	4.59
P/C	4.88
P/FCF	17.28
EV/EBITDA	-
EV/Sales	14.83
Quick Ratio	4.99
Current Ratio	4.99
Debt/Eq	0.06
LT Debt/Eq	0.05
Option/Short	Yes / Yes

EPS (ttm)	-0.54
EPS next Y	-2.28
EPS next Q	-0.41
EPS this Y	-22.73%
EPS next Y	-68.74%
EPS next 5Y	-
EPS past 3/5Y	-18.79% -
Sales past 3/5Y	- -
EPS Y/Y TTM	74.95%
Sales Y/Y TTM	13520.11%
EPS Q/Q	48.54%
Sales Q/Q	22375.63%
Earnings	Aug 10 AMC
EPS/Sales Surpr.	31.92% 39.14%

Insider Own	37.51%
Insider Trans	-8.59%
Inst Own	64.78%
Inst Trans	2.43%
ROA	-4.94%
ROE	-6.34%
ROIC	-5.96%
Gross Margin	98.33%
Oper. Margin	-56.68%
Profit Margin	-24.51%
SMA20	-6.21%
SMA50	4.21%
SMA200	32.89%
Trades

Shs Outstand	45.67M
Shs Float	29.17M
Short Float	9.85%
Short Ratio	6.52
Short Interest	2.87M
52W High	51.10 -23.86%
52W Low	11.70 232.56%
Volatility	4.00% 6.27%
ATR (14)	2.29
RSI (14)	47.33
Beta	2.32
Rel Volume	0.88
Avg Volume	440.60K
Volume	385,881

Perf Week	-2.72%
Perf Month	10.60%
Perf Quarter	28.84%
Perf Half Y	34.08%
Perf YTD	39.56%
Perf Year	216.86%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	54.22
Prev Close	40.47
Price	38.91
Change %	-3.85%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-11-26	Initiated	Guggenheim	Buy	$52
May-01-26	Initiated	Stifel	Buy	$43
Dec-19-25	Initiated	Raymond James	Strong Buy	$38
Dec-15-25	Initiated	Truist	Buy	$34
Nov-14-25	Upgrade	Wells Fargo	Equal Weight → Overweight
Jun-23-25	Initiated	H.C. Wainwright	Buy	$26
Feb-18-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$14
Nov-19-24	Initiated	Wells Fargo	Overweight	$43
Nov-19-24	Initiated	TD Cowen	Buy
Nov-19-24	Initiated	JP Morgan	Overweight	$38
Nov-19-24	Initiated	Cantor Fitzgerald	Overweight	$50

Show Previous Ratings

Aug-25-26 08:00AM	Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer (GlobeNewswire)
Aug-10-26 04:01PM	Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results (GlobeNewswire) +22.93%
Jun-08-26 08:00AM	Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting (Business Wire)
May-11-26 04:01PM	Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results (GlobeNewswire) +5.39%
May-05-26 08:00AM	Septerna to Present at Bank of America Securities Health Care Conference (GlobeNewswire)
08:00AM	Loading…
Apr-13-26 08:00AM	Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism (GlobeNewswire)
Mar-09-26 05:20PM	Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-01-26 09:45AM	Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy (GlobeNewswire)
Feb-24-26 08:00AM	Septerna to Present at TD Cowen 46th Annual Health Care Conference (GlobeNewswire) +10.21%
Feb-10-26 04:05PM	Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting (GlobeNewswire)
Jan-08-26 04:05PM	Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer (GlobeNewswire)
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly)
Dec-17-25 08:00AM	Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
08:00AM	Loading…
Nov-25-25 08:00AM	Septerna to Participate in 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-10-25 08:20AM	Septerna, Inc. (SEPN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-06-25 09:15AM	Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-03-25 08:00AM	Septerna to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-31-25 04:56AM	Strength Seen in Moderna (MRNA): Can Its 13.9% Jump Turn into More Strength? (Zacks)
Oct-22-25 05:57AM	Arcturus Therapeutics (ARCT) Moves 7.7% Higher: Will This Strength Last? (Zacks)
Oct-15-25 04:15PM	Novo Nordisk's Akero Therapeutics Buy Targets Eli Lilly's Lead (MarketBeat)
Oct-09-25 10:13AM	Strength Seen in Septerna, Inc. (SEPN): Can Its 7.0% Jump Turn into More Strength? (Zacks)
Oct-03-25 08:42AM	Are Options Traders Betting on a Big Move in Septerna Stock? (Zacks)
Sep-29-25 04:01PM	Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors (GlobeNewswire)
Aug-27-25 08:00AM	Septerna to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-21-25 08:00AM	Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases (GlobeNewswire) +5.50%
Aug-14-25 08:15AM	Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI (Reuters)
Aug-11-25 04:01PM	Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
08:00AM	Loading…
May-29-25 08:00AM	Septerna to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-23-25 07:45AM	Analysts Think These Stocks Could More Than Double in Value (MarketBeat)
May-21-25 09:55AM	Does Septerna, Inc. (SEPN) Have the Potential to Rally 151.27% as Wall Street Analysts Expect? (Zacks)
May-15-25 04:01PM	Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results (GlobeNewswire)
10:00AM	ETFs to Capitalize on the Novo Nordisk-Septerna Deal (Zacks)
08:46AM	Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk (Zacks)
07:45AM	Is It Time to Buy the Dip in Novo Nordisk Stock? (MarketBeat)
01:45AM	Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills (The Wall Street Journal)
May-14-25 04:06PM	Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing (Investor's Business Daily) +50.97%
02:22PM	eToro's Nasdaq debut, Exelixis outlook, SepternaNovo deal (Yahoo Finance Video)
01:29PM	Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies (Pharmaceutical Technology)
10:28AM	Novo Nordisk Rises on Weight-Loss News. Its a Huge Deal for This Stock. (Barrons.com)
09:35AM	Novo Nordisk, Septerna sign $2.2B deal to develop weight-loss pill (Yahoo Finance Video)
09:32AM	Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna (Yahoo Finance)
09:32AM	Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna (Yahoo Finance)
07:03AM	Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments (Reuters)
Apr-16-25 09:55AM	Wall Street Analysts Predict a 207.31% Upside in Septerna, Inc. (SEPN): Here's What You Should Know (Zacks)
Mar-31-25 02:34PM	Biotech Stocks Q1 2025 Recap: Winners And Underperformers (Seeking Alpha) -5.08%
Mar-27-25 08:00AM	Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-14-25 11:26AM	Septerna, Inc. (SEPN): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-05-25 06:59PM	Septerna, Inc. (SEPN): Among The Stocks With At Least $30 Million In Insider Spending Recently (Insider Monkey) +7.25%
Feb-26-25 08:00AM	Septerna to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 08:00AM	Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist (GlobeNewswire) -46.99%
Feb-14-25 06:45AM	Its not for the faint of heart. How 3 CEOs took their biotechs public (BioPharma Dive) +12.21%
Feb-06-25 07:48AM	Septerna, Inc. (SEPN): Among the Best Rebound Stocks to Invest In Now (Insider Monkey)
Jan-06-25 07:00AM	Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer (GlobeNewswire) -6.75%
Dec-18-24 08:00AM	Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-21-24 11:12PM	Septerna, Inc. Reports Q3 2024 Financials and Progress (TipRanks)
Nov-20-24 07:00AM	Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) -7.02%
05:10AM	Septerna initiated with an Overweight at JPMorgan (TipRanks)
Oct-30-24 04:41PM	Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering (GlobeNewswire) +12.32%
Oct-24-24 09:47PM	Septerna Prices Upsized Initial Public Offering (GlobeNewswire)

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.

Ph.D.Dr. Jeffrey T. Finer M.D.

M.S.Ms. Elizabeth P. Bhatt M.B.A.

J.D.Mr. Gilbert M. Labrucherie C.F.A.

Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory BoardDr. Robert J. Lefkowitz M.D.

Ph.D.Dr. Arthur Christopoulos BPHARM

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	Aug 12 '26	Sale	42.50	1,493,000	63,452,500	725,443	Aug 14 05:11 PM
Bhatt Elizabeth	President and COO	Aug 11 '26	Option Exercise	5.79	25,000	144,658	199,209	Aug 13 07:00 PM
Bhatt Elizabeth	President and COO	Aug 11 '26	Sale	44.00	25,000	1,100,000	174,209	Aug 13 07:00 PM
RA Capital Healthcare Fund LP	affiliate	Aug 12 '26	Proposed Sale	48.19	746,500	35,973,835		Aug 12 07:06 PM
RA Capital Nexus Fund III, L.P	Affiliate	Aug 12 '26	Proposed Sale	48.19	746,500	35,973,835		Aug 12 06:55 PM
Third Rock Ventures V, L.P.	10% Owner	Aug 12 '26	Proposed Sale	51.00	147,200	7,507,200		Aug 12 04:09 PM
ELIZABETH P. BHATT	Officer	Aug 11 '26	Proposed Sale	38.85	29,000	1,126,650		Aug 11 04:28 PM
Long Daniel D.	SVP, Drug Discovery	Aug 03 '26	Option Exercise	2.76	3,334	9,202	99,746	Aug 05 07:00 PM
Long Daniel D.	SVP, Drug Discovery	Aug 03 '26	Sale	34.47	3,334	114,920	96,412	Aug 05 07:00 PM
Bhatt Elizabeth	President and COO	Jul 15 '26	Option Exercise	6.81	4,000	27,240	178,209	Jul 17 07:00 PM
Bhatt Elizabeth	President and COO	Jul 15 '26	Sale	33.99	4,000	135,974	174,209	Jul 17 07:00 PM
ELIZABETH P. BHATT	Officer	Jul 15 '26	Proposed Sale	34.54	4,000	138,160		Jul 15 04:23 PM
Long Daniel D.	SVP, Drug Discovery	Jul 01 '26	Option Exercise	2.76	3,333	9,199	99,745	Jul 02 07:00 PM
Long Daniel D.	SVP, Drug Discovery	Jul 01 '26	Sale	34.36	3,333	114,528	96,412	Jul 02 07:00 PM
Shaikhly Samira	Chief People Officer	Jun 29 '26	Option Exercise	6.81	2,178	14,832	2,971	Jun 30 07:01 PM
Shaikhly Samira	Chief People Officer	Jun 29 '26	Sale	35.18	2,178	76,622	793	Jun 30 07:01 PM
JAE KIM	Officer	Jun 26 '26	Proposed Sale	36.61	2,438	89,243		Jun 26 04:02 PM
Long Daniel D.	SVP, Drug Discovery	Jun 22 '26	Option Exercise	5.42	15,000	81,371	111,412	Jun 24 07:24 PM
Long Daniel D.	SVP, Drug Discovery	Jun 22 '26	Sale	35.51	15,000	532,582	96,412	Jun 24 07:24 PM
DANIEL LONG	Officer	Jun 22 '26	Proposed Sale	36.17	25,000	904,250		Jun 22 04:40 PM
JAE KIM	Officer	Jun 22 '26	Proposed Sale	35.26	94,339	3,326,120		Jun 22 04:16 PM
Shaikhly Samira	Chief People Officer	Jun 12 '26	Option Exercise	11.70	6,250	73,125	7,043	Jun 16 08:31 PM
Shaikhly Samira	Chief People Officer	Jun 12 '26	Sale	35.08	6,250	219,224	793	Jun 16 08:31 PM
SAMIRA SHAIKHLY	Officer	Jun 12 '26	Proposed Sale	34.03	8,428	286,805		Jun 12 04:42 PM
Shaikhly Samira	Chief People Officer	Jun 01 '26	Option Exercise	1.87	5,935	11,111	6,728	Jun 03 07:11 PM
Shaikhly Samira	Chief People Officer	Jun 01 '26	Sale	28.93	5,935	171,682	793	Jun 03 07:11 PM
Shaikhly Samira	Chief People Officer	May 26 '26	Option Exercise	6.81	11,798	80,344	12,591	May 28 07:02 PM
Shaikhly Samira	Chief People Officer	May 26 '26	Sale	30.06	11,798	354,656	793	May 28 07:02 PM
SAMIRA SHAIKHLY	Officer	May 26 '26	Proposed Sale	28.36	11,798	334,591		May 26 04:41 PM
Bhatt Elizabeth	President and COO	Apr 15 '26	Option Exercise	6.81	4,000	27,240	178,209	Apr 17 07:00 PM
Bhatt Elizabeth	President and COO	Apr 15 '26	Sale	24.34	4,000	97,343	174,209	Apr 17 07:00 PM
Shaikhly Samira	Chief People Officer	Mar 02 '26	Option Exercise	1.84	70,453	129,456	71,246	Mar 04 07:00 PM
Shaikhly Samira	Chief People Officer	Mar 02 '26	Sale	28.10	70,453	1,979,838	793	Mar 04 07:00 PM
SAMIRA SHAIKHLY	Officer	Mar 02 '26	Proposed Sale	29.02	76,388	2,216,780		Mar 02 04:36 PM
Bhatt Elizabeth	President and COO	Feb 18 '26	Option Exercise	6.81	4,000	27,240	178,209	Feb 20 05:28 PM
Bhatt Elizabeth	President and COO	Feb 18 '26	Sale	28.97	4,000	115,860	174,209	Feb 20 05:28 PM
ELIZABETH BHATT	Officer	Feb 18 '26	Proposed Sale	30.30	8,000	242,400		Feb 18 04:27 PM
Long Daniel D.	SVP, Drug Discovery	Nov 10 '25	Sale	18.06	3,501	63,223	92,911	Nov 13 08:13 PM
DANIEL DAVID LONG	Officer	Nov 10 '25	Proposed Sale	18.06	3,501	63,223		Nov 10 04:07 PM

Open in Screener

RAPP

Rapport Therapeutics Inc

48.77

Aug 28 • 3:59 PM ET -2.06 (-4.05%)

48.77

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

RAPP Rapport Therapeutics Inc daily Stock Chart

Peers: DNLI ACAD XENE KYMR CRNX AXSM INCY KRYS BIIB NBIX

| Held by: VTI IWM VXF IWO IBB XPH VTWO SCHA DFAS IHE

Index	RUT
Market Cap	2.34B
Enterprise Value	1.91B
Income	-137.16M
Sales	20.00M
Book/sh	8.82
Cash/sh	9.09
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	84
IPO	Jun 07, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	117.00
P/B	5.53
P/C	5.36
P/FCF	-
EV/EBITDA	-
EV/Sales	95.69
Quick Ratio	15.72
Current Ratio	15.72
Debt/Eq	0.02
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-3.04
EPS next Y	-4.94
EPS next Q	-1.21
EPS this Y	-41.32%
EPS next Y	-22.25%
EPS next 5Y	-24.34%
EPS past 3/5Y	-114.24% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-23.53%
Sales Y/Y TTM	-
EPS Q/Q	-58.13%
Sales Q/Q	-
Earnings	Aug 05 BMO
EPS/Sales Surpr.	-6.29% -

Insider Own	40.28%
Insider Trans	-5.23%
Inst Own	75.32%
Inst Trans	-0.08%
ROA	-36.85%
ROE	-39.96%
ROIC	-31.86%
Gross Margin	95.20%
Oper. Margin	-767.58%
Profit Margin	-685.80%
SMA20	2.59%
SMA50	12.46%
SMA200	42.45%
Trades

Shs Outstand	47.96M
Shs Float	28.65M
Short Float	7.77%
Short Ratio	6.33
Short Interest	2.23M
52W High	52.93 -7.86%
52W Low	14.11 245.64%
Volatility	5.20% 4.77%
ATR (14)	2.27
RSI (14)	56.70
Beta	1.08
Rel Volume	0.95
Avg Volume	351.82K
Volume	332,731

Perf Week	1.10%
Perf Month	14.00%
Perf Quarter	23.47%
Perf Half Y	68.00%
Perf YTD	60.74%
Perf Year	190.30%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	62.25
Prev Close	50.83
Price	48.77
Change %	-4.05%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-28-26	Initiated	William Blair	Outperform
Jun-24-26	Initiated	Leerink Partners	Outperform	$52
May-19-26	Resumed	Truist	Buy	$56
Apr-10-26	Initiated	Raymond James	Strong Buy	$66
Feb-02-26	Initiated	Wells Fargo	Overweight	$43
Nov-19-25	Initiated	BTIG Research	Buy	$47
Sep-16-25	Initiated	Truist	Buy	$44
Aug-06-25	Initiated	H.C. Wainwright	Buy	$31
Apr-08-25	Initiated	Citizens JMP	Mkt Outperform
Jul-02-24	Initiated	TD Cowen	Buy
Jul-02-24	Initiated	Stifel	Buy	$35
Jul-02-24	Initiated	Jefferies	Buy	$35

Show Previous Ratings

Aug-24-26 07:00AM	Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program (GlobeNewswire)
Aug-05-26 07:00AM	Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update (GlobeNewswire)
May-20-26 04:05PM	Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire)
May-07-26 07:00AM	Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update (GlobeNewswire) +7.74%
Apr-21-26 04:30PM	Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting (GlobeNewswire)
07:00AM	Loading…
Apr-01-26 07:00AM	Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-10-26 07:00AM	Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-09-26 09:26AM	Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures (Benzinga)
07:00AM	Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China (GlobeNewswire)
Feb-24-26 04:05PM	Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-07-26 07:00AM	Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline (GlobeNewswire) +8.89%
Dec-18-25 07:00AM	Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-08-25 12:00PM	Rapport Therapeutics, Inc. (RAPP) Is Up 9.03% in One Week: What You Should Know (Zacks)
Dec-05-25 09:00AM	Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219's Clinical Response in Patients with Focal Onset Seizures (GlobeNewswire)
Nov-28-25 09:55AM	Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High? (Zacks)
07:00AM	Loading…
Nov-25-25 07:00AM	Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting (GlobeNewswire)
Nov-12-25 09:55AM	Wall Street Analysts Think Rapport Therapeutics, Inc. (RAPP) Could Surge 104.47%: Read This Before Placing a Bet (Zacks)
Nov-06-25 07:00AM	Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update (GlobeNewswire)
Nov-05-25 04:05PM	Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-30-25 11:49AM	JMP Sees Big Gains in Rapport Therapeutics, Inc. (RAPP) After Focal Epilepsy Study Success (Insider Monkey) +6.19%
Sep-12-25 11:13AM	RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal (Zacks)
Sep-11-25 04:05PM	Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (GlobeNewswire)
Sep-09-25 09:17PM	Rapport Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -10.93% -20.09%
Sep-08-25 04:08PM	Rapport Stock Doubles After Succeeding In Hard-To-Treat Seizures (Investor's Business Daily) +119.15%
04:05PM	Rapport Announces Proposed Public Offering of Common Stock (GlobeNewswire)
09:45AM	Rapport Catapults Almost 200% After Succeeding In Hard-To-Treat Seizures (Investor's Business Daily)
09:28AM	Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year (Benzinga)
06:00AM	Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures (GlobeNewswire)
Sep-05-25 04:05PM	Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025 (GlobeNewswire) -6.45%
Aug-13-25 08:03AM	Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors (Business Wire)
07:00AM	Loading…
Aug-07-25 07:00AM	Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update (GlobeNewswire) +5.48%
Jun-12-25 01:57PM	Analysts Can't Get Enough of These Little-Known Biopharma Stocks (MarketBeat) -7.93%
Jun-02-25 02:45PM	Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates (GlobeNewswire) +13.66%
May-27-25 07:00AM	Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire) -7.21%
May-21-25 07:00AM	Rapport Therapeutics to Host 2025 Investor and Analyst Day (GlobeNewswire)
May-08-25 07:00AM	Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update (GlobeNewswire)
Apr-22-25 07:00AM	Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +11.27%
Mar-31-25 04:33AM	Rapport Therapeutics: Too Early To Be Interesting (Seeking Alpha)
Mar-21-25 07:00AM	Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting (GlobeNewswire)
Mar-11-25 07:00AM	Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) +8.34%
Mar-03-25 07:00AM	Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development (GlobeNewswire) -28.71%
Feb-24-25 07:00AM	Rapport Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-10-25 07:20AM	Rapport Therapeutics announces new Phase 1 data for RAP-219 (TipRanks) -11.26%
Jan-09-25 09:12AM	CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders (GlobeNewswire)
07:00AM	Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders (GlobeNewswire)
Dec-06-24 12:01PM	Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures (GlobeNewswire)
Nov-14-24 07:00AM	Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting (GlobeNewswire)
Nov-08-24 07:18AM	Rapport Therapeutics expects cash to fund requirements through 2026 (TipRanks)
Nov-07-24 07:00AM	Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update (GlobeNewswire)
Nov-04-24 07:00AM	Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November (GlobeNewswire)
Sep-05-24 07:00AM	Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences (GlobeNewswire)
Aug-29-24 07:00AM	Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit (GlobeNewswire)
Aug-08-24 07:00AM	Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update (GlobeNewswire)
Aug-06-24 06:30AM	3 Under-The-Radar Healthcare Stocks to Buy for Outsized Returns (InvestorPlace)
Jul-29-24 07:00AM	Rapport Therapeutics to Present Data for TARP 8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain (GlobeNewswire)
Jul-05-24 02:22PM	Hedge Fund and Insider Trading News: Bill Ackman, Segantii Capital Management Ltd, Rapport Therapeutics Inc (RAPP), Archer Aviation Inc (ACHR), and More (Insider Monkey)
Jun-12-24 04:01PM	Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement (GlobeNewswire) +9.02%
Jun-06-24 06:54PM	Rapport Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Founder & Independent ChairmanDr. Steven M. Paul M.D.

CEOMr. Abraham N. Ceesay M.B.A.

Chief Financial OfficerMr. Troy A. Ignelzi

Chief Medical OfficerDr. Jeffrey Sevigny M.D.

Ph.D.Dr. David Bredt M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ceesay Abraham	Chief Executive Officer	Aug 25 '26	Sale	49.57	18,921	937,957	467,187	Aug 26 04:05 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Aug 25 '26	Sale	50.64	37,000	1,873,605	195,862	Aug 26 04:00 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Aug 24 '26	Sale	50.00	13,160	657,978	232,862	Aug 26 04:00 PM
KRISHNASWAMY YELESWARAM	Officer	Aug 25 '26	Proposed Sale	49.33	37,000	1,825,210		Aug 25 04:29 PM
KRISHNASWAMY YELESWARAM	Officer	Aug 24 '26	Proposed Sale	48.24	11,472	553,409		Aug 24 04:28 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Aug 19 '26	Sale	49.90	404	20,160	246,022	Aug 20 04:09 PM
KRISHNASWAMY YELESWARAM	Officer	Aug 19 '26	Proposed Sale	49.01	2,092	102,529		Aug 19 04:38 PM
Ceesay Abraham	Chief Executive Officer	Aug 11 '26	Sale	48.01	28,958	1,390,405	486,108	Aug 12 04:35 PM
Ceesay Abraham	Chief Executive Officer	Aug 10 '26	Sale	46.26	22,541	1,042,772	515,066	Aug 12 04:35 PM
Ceesay Abraham	Chief Executive Officer	Jul 27 '26	Sale	42.11	2,210	93,061	537,607	Jul 29 04:05 PM
Ceesay Abraham	Chief Executive Officer	Jul 14 '26	Sale	40.00	8,210	328,437	539,817	Jul 15 04:15 PM
Gault Cheryl	Chief Operating Officer	Jun 30 '26	Sale	41.58	10,000	415,798	149,914	Jul 01 04:10 PM
Ceesay Abraham	Chief Executive Officer	Jun 29 '26	Sale	39.83	8,220	327,398	548,027	Jul 01 04:05 PM
CHERYL GAULT	Officer	Jun 30 '26	Proposed Sale	40.39	10,000	403,900		Jun 30 04:33 PM
Abraham N. Ceesay	Officer	Jun 29 '26	Proposed Sale	40.39	99,480	4,017,997		Jun 29 04:45 PM
Third Rock Ventures V, L.P.	10% Owner	May 26 '26	Sale	40.05	18,572	743,753	6,280,525	May 28 04:15 PM
Third Rock Ventures V, L.P.	10% Owner	May 26 '26	Proposed Sale	40.00	18,572	742,880		May 27 09:16 AM
Third Rock Ventures V, L.P.	10% Owner	May 11 '26	Sale	40.24	133,618	5,377,323	6,299,097	May 13 07:06 PM
Third Rock Ventures V, L.P.	10% Owner	May 07 '26	Sale	40.12	271,495	10,892,651	6,437,733	May 11 05:07 PM
Third Rock Ventures V, L.P.	10% Owner	May 08 '26	Sale	40.31	5,018	202,256	6,432,715	May 11 05:07 PM
Third Rock Ventures V, L.P.	10% Owner	May 11 '26	Proposed Sale	40.25	133,618	5,378,124		May 11 04:25 PM
Third Rock Ventures V, L.P.	10% Owner	May 08 '26	Proposed Sale	40.31	5,018	202,254		May 08 04:57 PM
Third Rock Ventures V, L.P.	10% Owner	May 07 '26	Proposed Sale	40.12	271,495	10,892,705		May 07 04:44 PM
Third Rock Ventures V, L.P.	10% Owner	Apr 17 '26	Sale	40.32	426,005	17,175,244	6,709,228	Apr 21 07:36 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Apr 17 '26	Sale	39.99	20,225	808,844	246,426	Apr 21 04:55 PM
KRISHNASWAMY YELESWARAM	Officer	Apr 17 '26	Proposed Sale	39.54	20,225	799,696		Apr 17 04:37 PM
Third Rock Ventures V, L.P.	10% Owner	Apr 17 '26	Proposed Sale	40.32	426,005	17,175,116		Apr 17 04:25 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Apr 14 '26	Sale	35.08	10,200	357,797	266,651	Apr 14 04:13 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Apr 13 '26	Sale	34.97	9,165	320,537	276,851	Apr 14 04:13 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Apr 10 '26	Sale	34.98	500	17,490	286,016	Apr 14 04:13 PM
KRISHNASWAMY YELESWARAM	Officer	Apr 13 '26	Proposed Sale	34.17	19,365	661,702		Apr 13 04:37 PM
KRISHNASWAMY YELESWARAM	Officer	Apr 10 '26	Proposed Sale	34.22	500	17,110		Apr 10 04:34 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Apr 08 '26	Sale	34.90	360	12,564	286,516	Apr 09 04:30 PM
KRISHNASWAMY YELESWARAM	Officer	Apr 08 '26	Proposed Sale	33.49	360	12,056		Apr 08 05:35 PM
Gault Cheryl	Chief Operating Officer	Mar 30 '26	Sale	28.19	10,000	281,857	159,914	Mar 31 04:27 PM
CHERYL GAULT	Officer	Mar 30 '26	Proposed Sale	27.84	10,000	278,400		Mar 30 05:31 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Mar 25 '26	Sale	29.99	10,115	303,355	286,876	Mar 26 04:41 PM
KRISHNASWAMY YELESWARAM	Officer	Mar 25 '26	Proposed Sale	28.25	10,115	285,749		Mar 25 04:22 PM
Gault Cheryl	Chief Operating Officer	Mar 05 '26	Sale	28.93	2,014	58,265	169,914	Mar 09 04:07 PM
Gault Cheryl	Officer	Mar 05 '26	Proposed Sale	28.92	2,014	58,236		Mar 05 05:54 PM
Ceesay Abraham	Chief Executive Officer	Feb 18 '26	Sale	29.34	5,833	171,161	556,247	Feb 19 07:06 PM
Ceesay Abraham	Chief Executive Officer	Feb 18 '26	Sale	29.36	5,083	149,212	20,729	Feb 19 07:06 PM
Bredt David	Chief Scientific Officer	Feb 19 '26	Option Exercise	1.80	6,000	10,800	393,075	Feb 19 07:05 PM
Bredt David	Chief Scientific Officer	Feb 17 '26	Sale	29.02	8,500	246,655	387,075	Feb 19 07:05 PM
Ceesay Abraham	Chief Executive Officer	Jan 20 '26	Sale	26.12	5,833	152,333	562,080	Jan 22 07:00 PM
Ceesay Abraham	Chief Executive Officer	Jan 20 '26	Sale	26.11	5,083	132,737	25,812	Jan 22 07:00 PM
Bredt David	Chief Scientific Officer	Jan 15 '26	Sale	26.84	8,500	228,132	395,575	Jan 16 04:06 PM
DAVID BREDT	Officer	Jan 15 '26	Proposed Sale	27.42	17,000	466,140		Jan 15 04:28 PM
Bredt David	Chief Scientific Officer	Dec 31 '25	Sale	30.05	6,567	197,338	404,075	Jan 05 04:20 PM
Yeleswaram Krishnaswamy	Chief Development Officer	Dec 31 '25	Sale	30.05	2,840	85,342	296,991	Jan 05 04:19 PM
DAVID BREDT	Officer	Jan 02 '26	Proposed Sale	30.05	6,567	197,338		Jan 02 08:20 PM
Krishnaswamy Yeleswaram	Officer	Jan 02 '26	Proposed Sale	30.05	2,840	85,343		Jan 02 08:17 PM
Ceesay Abraham	Chief Executive Officer	Dec 17 '25	Sale	29.64	5,833	172,877	567,913	Dec 18 04:11 PM
Ceesay Abraham	Chief Executive Officer	Dec 17 '25	Sale	29.63	5,083	150,632	30,895	Dec 18 04:11 PM
THE DOROTHY CEESAY IRREVOCABLE	Director	Dec 17 '25	Proposed Sale	30.76	15,249	469,059		Dec 17 04:28 PM
ABRAHAM CEESAY	Director	Dec 17 '25	Proposed Sale	30.76	17,499	538,269		Dec 17 04:25 PM
Bredt David	Chief Scientific Officer	Dec 15 '25	Sale	30.02	8,500	255,130	392,642	Dec 16 05:07 PM
Gault Cheryl	Chief Operating Officer	Nov 26 '25	Option Exercise	1.80	5,000	9,000	176,928	Dec 01 04:17 PM
Gault Cheryl	Chief Operating Officer	Nov 26 '25	Sale	30.10	5,000	150,486	171,928	Dec 01 04:17 PM
Ceesay Abraham	Chief Executive Officer	Nov 17 '25	Sale	25.19	5,833	146,931	573,746	Nov 18 04:27 PM
Ceesay Abraham	Chief Executive Officer	Nov 17 '25	Sale	25.20	5,083	128,116	35,978	Nov 18 04:27 PM
Bredt David	Chief Scientific Officer	Nov 17 '25	Sale	25.19	8,500	214,091	401,142	Nov 18 04:24 PM
Bredt David	Chief Scientific Officer	Oct 15 '25	Sale	25.79	8,500	219,196	409,642	Oct 16 04:30 PM
Ceesay Abraham	Chief Executive Officer	Oct 15 '25	Sale	25.81	5,833	150,541	579,579	Oct 16 04:30 PM
Ceesay Abraham	Chief Executive Officer	Oct 15 '25	Sale	25.81	5,083	131,189	41,061	Oct 16 04:30 PM
DAVID BREDT	Officer	Oct 15 '25	Proposed Sale	24.88	25,500	634,440		Oct 15 04:26 PM
Ceesay Abraham	Chief Executive Officer	Sep 17 '25	Sale	26.32	40,835	1,074,725	585,412	Sep 19 04:05 PM
Ceesay Abraham	Chief Executive Officer	Sep 17 '25	Sale	26.32	35,585	936,472	46,144	Sep 19 04:05 PM
ABRAHAM CEESAY	Director	Sep 17 '25	Proposed Sale	26.19	52,501	1,375,001		Sep 17 04:28 PM
THE DOROTHY CEESAY IRREV TRUST	Director	Sep 17 '25	Proposed Sale	26.19	45,751	1,198,219		Sep 17 04:26 PM
Bredt David	Chief Scientific Officer	Sep 15 '25	Sale	24.19	8,500	205,649	418,142	Sep 17 04:15 PM
Huber Reid M	Director	Sep 12 '25	Buy	24.48	20,400	499,374	20,400	Sep 15 04:05 PM
PAUL STEVEN M	Director	Sep 12 '25	Buy	24.65	41,666	1,027,111	41,666	Sep 15 04:05 PM
Young Wendy B.	Director	Sep 11 '25	Buy	22.60	3,500	79,100	9,500	Sep 11 06:13 PM
Gault Cheryl	Chief Operating Officer	Sep 08 '25	Option Exercise	1.80	5,000	9,000	176,928	Sep 10 04:15 PM
Gault Cheryl	Chief Operating Officer	Sep 08 '25	Sale	38.33	5,000	191,650	171,928	Sep 10 04:15 PM
CHERYL GAULT	Officer	Sep 08 '25	Proposed Sale	14.36	10,000	143,600		Sep 08 04:24 PM

SEPN

Septerna Inc

RAPP

Rapport Therapeutics Inc

Upgrade your Finviz experience